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REVIEW

Management of anticoagulant-related intracranial
hemorrhage: an evidence-based review
Bappaditya Ray1* and Salah G Keyrouz2

Abstract
The increased use of anticoagulants for the prevention
and treatment of thromboembolic diseases has led to a
rising incidence of anticoagulant-related intracranial
hemorrhage (AICH) in the aging western population.
High mortality accompanies this form of hemorrhagic
stroke, and significant and debilitating long-term
consequences plague survivors. Although management
guidelines for such hemorrhages are available for the
older generation anticoagulants, they are still lacking for
newer agents, which are becoming popular among
physicians. Supportive care, including blood pressure
control, and reversal of anticoagulation remain the
cornerstone of acute management of AICH. Prothrombin
complex concentrates are gaining popularity over
fresh frozen plasma, and reversal agents for newer
anticoagulation agents are being developed. Surgical
interventions are options fraught with complications,
and are decided on a case-by-case basis. Our current
state of understanding of this condition and its
management is insufficient. This deficit calls for more
population-based studies and therapeutic trials to better
evaluate risk factors for, and to prevent and treat AICH.

Introduction
Use of anticoagulation therapy among the older western
population for varied thromboembolic diseases potentially
places them at risk of developing anticoagulant-related
intracranial hemorrhage (AICH). The indications for use of
anticoagulants are published in a guideline statement by
the American College of Chest Physicians [1], to which
readers are referred. AICH can be spontaneous or traumatic, and can occur in different intracranial compartments
(for example, subdural hemorrhage, epidural hemorrhage,
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subarachnoid hemorrhage, or intracerebral hemorrhage
(ICH)). Most clinical data on AICH are related to ICH,
while extraparenchymal hemorrhages are reported but data
on these are sparse.
In the absence of clinical evidence, definitive guidelines,
and proven therapies, clinicians are left scrambling for
rapid correction of the coagulopathy and maintaining
homeostasis to prevent secondary brain injury. The basic
pharmacological properties of commonly used anticoagulants, their mechanism of action, and their indications are
presented in Table 1 and Figure 1. Interested readers are
referred to recently published articles for in-depth reviews
of these agents [2,3]. The present review will primarily
focus on the importance and impact of AICH, and, where
available, the evidence-based management of this mostly
iatrogenic disease.

Epidemiology
The use of anticoagulants has increased exponentially over
the last two decades along with the incidence of atrial
fibrillation in aging western populations [4-6]; 5.6 million
patients in the USA will be on anticoagulation for atrial fibrillation by 2050 [7]. With this increased use, the incidence
of AICH has risen; the Greater Cincinnati area has seen a
threefold increase in incidence during a 10-year period [8].
It is unclear whether a similar trend is still persistent with
the introduction of newer generation oral anticoagulants
(see below). Warfarin – the most commonly used, and
therefore most extensively studied, long-term oral anticoagulant – is responsible for 9 to 14% of ICH [9-11] and
carries 0.3 to 3.7% annual risk of warfarin-related intracerebral hemorrhage (WRICH) when the International Normalized Ratio (INR) is between 2 and 4.5 [12]. The risk of ICH
in patients on long-term anticoagulation is 8 to 11 times
higher than that of age-matched cohorts not taking anticoagulants [13,14]. Advanced age (≥70 years) [15,16], hypertension [9,14,15,17] and concurrent use of single or dual
antiplatelets [18] are risk factors for WRICH. Other established risk factors include the early period after warfarin
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Drug

Target

Antithrombin Route
dependent

Half-life (hours)

Protein Renal excretion
binding

Monitoring

Antidote

Common indications

Warfarin

Factors II, VII, IX, X; No
proteins C, S

p.o.

30 to 40

99%

INR

Vitamin K

Thromboembolic prophylaxis in
AF. Treatment of VTE. Thrombosis
prophylaxis in prosthetic valve

UFH

Factors II, Xa
Yes
(VIIa, IXa, XIa, XIIa)

i.v., s.c.

0.5 to 2.5
(dose dependent)

Variable Mostly after
aPTT
hepatic metabolism

Protamine sulfate ACS. Thromboprophylaxis.
Thromboembolic diseases
(including ischemic stroke,
CVST) in acute phase

LMWH

Factors IIa, Xa

Yes

s.c., i.v.

Variable according
to the product

Variable 40% (10%
unchanged)

Anti-factor Xa

Protamine
sulfate (60%)

ACS. Thromboprophylaxis.
Thromboembolic diseases

Fondaparinux Factor Xa

Yes

s.c.

17 to 21

94%

~100% (77%
unchanged)

Anti-factor Xa

None (see text)

VTE. Thromboprophylaxis. Selected
cases of HIT

Argatroban

Factor IIa

No

i.v.

0.75 (prolonged in
54%
hepatic dysfunction)

22% (16%
unchanged)

aPTT, ACT

None

HIT. Thromboprophylaxis in
patients suspected of HIT. ACS

Bivalirudin

Factor IIa

No

i.v.

0.5 (prolonged in
renal impairment)

Only to
factor
IIa

20% unchanged

ECT (PT, aPTT, ACT has
nonlinear prolongation)

None

HIT. ACS after thrombolysis.
Thromboembolic prophylaxis
during interventional procedures

Dabigatran

Factor IIa

No

p.o.

12 to 14

35%

80%

Modified TT/ECT/antiPCC/FEIBA™/rFVIIa Thromboembolic prophylaxis in AF.
factor IIa (also see Table 3) (see text)
Treatment and thromboprophylaxis
of VTE

Apixaban

Factor Xa

No

p.o.

8 to 14

87%

~25%

Anti-factor Xa
(also see Table 3)

PCC/FEIBA™/rFVIIa Thromboembolic prophylaxis in AF.
(see text)
Treatment and thromboprophylaxis
of VTE

Rivaroxaban

Factor Xa

No

p.o.

7 to 11

93%

66% (33%
unchanged)

Anti-factor Xa
(also see Table 3)

PCC/FEIBA™/rFVIIa Thromboembolic prophylaxis in AF.
(see text)
Treatment and thromboprophylaxis
of VTE

92%
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Table 1 Pharmacologic properties of anticoagulants

ACS, acute coronary syndrome; ACT, activated clotting time; AF, atrial fibrillation; aPTT, activated partial thromboplastin time; CVST, cerebral venous sinus thrombosis; ECT, ecarin clotting time; HIT, heparin-induced
thrombocytopenia; INR, International Normalized Ratio; i.v., intravenous; LMWH, low molecular weight heparin; PCC, prothrombin complex concentrate; p.o., per oral; PT, prothrombin time; rFVIIa, activated recombinant
factor VII; s.c., subcutaneous; TT, thrombin time; UFH, unfractionated heparin; VTE, venous thromboembolism. FEIBA™ from Baxter (Deerfield, IL, USA).
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Figure 1 Clinically available anticoagulants and their sites of action. Dashed red arrows, sites of action. Italicized drugs are for parenteral
use. F, factor; LMWH, low molecular weight heparin; TF, tissue factor; UFH, unfractionated heparin.

initiation [9,13,19], supratherapeutic levels of anticoagulation [9,14,17,20-23] and associated leukoaraiosis [21,23].
Similarly, unfractionated heparin (UFH) – a parenteral
anticoagulant for various indications – also carries a risk of
AICH. The incidence of symptomatic ICH used with UFH
or heparinoids is 1 to 2.7% in patients with acute ischemic
stroke [24,25]. A direct thrombin inhibitor, argatroban, another commonly used short-term parenteral anticoagulant,
is associated with a 4.3% incidence of AICH [26].
In contrast, there are promising yet limited clinical data
on AICH associated with the use of newer oral anticoagulants. The results of recent clinical trials using these drugs
are presented in Table 2. The rates of ICH were 0.74%,
0.30%, and 0.23% per year among those assigned to warfarin, dabigatran 150 mg, and dabigatran 110 mg respectively in the RE-LY (Randomized Evaluation of Long Term
Anticoagulant Therapy) trial, which assessed the efficacy of
this oral direct thrombin inhibitor in atrial fibrillation [27].
In contrast, in the RE-COVER (Efficacy and Safety of
Dabigatran Compared to Warfarin for 6 Month Treatment
of Acute Symptomatic Venous Thromboembolism) trial,
which compared dabigatran and warfarin in acute venous
thromboembolism, there were no incidences of ICH during
6 months of therapy [28]. The yearly incidence of AICH
ranged between 0.33 and 0.35% for apixaban, an oral factor
Xa inhibitor, in two different trials – the ARISTOTLE
(Apixaban for Reduction in Stroke and Other Thromboembolic Events) trial and the AVERROES (Apixaban Versus
Acetylsalicylic Acid to Prevent Strokes) trial [29,30]. The incidence of AICH linked to rivaroxaban, another oral factor
Xa inhibitor, in the ROCKET-AF (Rivaroxaban Once-daily
Oral Direct Factor Xa Inhibition Compared with Vitamin K
Antagonism for Prevention of Stroke and Embolism Trial
in Atrial Fibrillation) study was 0.49%; that of warfarin was
0.74% (P < 0.05) [31]. However, in the EINSTEIN-PE (Oral
Rivaroxaban Alone for the Treatment of Symptomatic

Pulmonary Embolism) trial – a study that compared the
efficacy of rivaroxaban with that of enoxaparin followed by
warfarin in patients with pulmonary embolism – the incidence of AICH was lower for rivaroxaban (0.1% vs. 0.5%;
P = 0.003) [32]. For cerebrovascular indication, national
registry data showed similar peri-procedural incidence of
ICH with bivalirudin and UFH after carotid stenting
(0.1% vs. 0.2%; odds ratio = 0.62, 95% confidence interval
= 0.20 to 1.91; P = 0.41) [33].
Outcomes after AICH have been mostly studied in
patients on warfarin. Patients with WRICH fare worse than
those with ICH without coagulopathy, with case fatality
rates ranging between 44 and 68% [34-36]. In the Greater
Cincinnati study, patients on warfarin with INR > 3.0 had
larger hematomas than other patients [37]. After presentation, hematoma enlargement is more common and could
still occur beyond the first 24 hours in anticoagulated
patients [37-39]. What is more worrisome is that
hematoma could still expand despite rapid correction of
coagulopathy [40]. Little is known about the outcome of
patients with AICH related to the newer anticoagulants;
however, with an expected rise in use as they get wider
acceptance [41], physicians on the forefront are likely to
encounter more patients with such hemorrhages.

Management
There are several uncertainties in the management of
AICH. These uncertainties include the lack of evidence and
limited guidelines for using biological products and
pharmacologic agents, and accurate, quick, and meaningful
laboratory testing to evaluate the hemostatic system.
Moreover, individual variation in response to therapy and
the difficulty in assessing ongoing bleeding make it even
more challenging to manage this clinical problem [42]. One
should also note that the mere correction of a laboratory
parameter (that is, an ex vivo test) might not correlate with

Clinical trial

Indication

Inclusion criteria

Drug

Primary outcome

RE-LY

Stroke
prevention in
nonvalvular atrial
fibrillation

AF patients with moderate to high
risk of stroke or systemic embolism
with at least one of the following:
age >75 years; h/o TIA or stroke;
LVEF <40%; NYHA class II or higher;
age 65 to 74 years with either DM,
CAD, hypertension

Dabigatran 110 mg or 150 mg BID;
warfarin with target INR 2 to 3

AICH: dabigatran 110 mg, 0.23%/year;
Prevention of stroke/systemic
dabigatran 150 mg, 0.30%/year (P < 0.05);
embolism: dabigatran 110 mg,
1.54%/year; dabigatran 150 mg, warfarin, 0.74%/year
1.11%/year; warfarin, 1.71%/year

ROCKET-AF

Stroke
prevention in
nonvalvular atrial
fibrillation

AF with history of stroke or TIA.
AF with two or more of the following:
symptomatic heart failure or
LVEF <35%; age >75 years; DM

Rivaroxaban 20 mg daily; warfarin
with target INR 2 to 3

Prevention of stroke/systemic
embolism: rivaroxaban, 2.12%/
year; warfarin, 2.42%/year

ARISTOTLE

Stroke
prevention in
nonvalvular atrial
fibrillation

AF with one or more of following:
Apixaban 5 mg BID; warfarin with
TIA or systemic embolism; symptomatic target INR 2 to 3
CHF or LVEF ≤40%; DM or hypertension
on pharmacological treatment

Prevention of stroke/systemic
AICH: apixaban, 0.33%/year; warfarin,
embolism: apixaban, 1.27%/year; 0.80%/year
warfarin, 1.60%/year

RE-COVER

VTE recurrence
prevention

Acute symptomatic DVT of legs or PE

Dabigatran 150 mg BID; warfarin
with target INR 2 to 3

Thromboembolism or related
deaths: dabigatran, 2.4%;
warfarin, 2.1%

AICH: dabigatran, 0; warfarin, 0.24%

RECOVER II

VTE recurrence
prevention

Acute symptomatic DVT of legs or PE

Dabigatran 150 mg BID; heparin/enoxaparin
followed by warfarin with target INR 2 to 3

Recurrent VTE: dabigatran,
2.3%; warfarin, 2.2%

Not reported

EINSTEIN-DVT Prevention of
VTE recurrence

Acute symptomatic DVT

Rivaroxaban 15 mg BID × 3 weeks followed
by 20 mg daily. Standard therapy: enoxaparin
1 mg/kg BID; bridging warfarin or
acenocoumarol therapy with target INR 2
to 3

Recurrent VTE: rivaroxaban,
2.1%; enoxaparin-VKA, 3.0%

AICH data not reported separately.
Bleeding in critical location: rivaroxaban,
0.2%; enoxaparin-VKA, 0.2%

EINSTEIN-PE

Acute PE

Recurrent VTE: rivaroxaban,
Rivaroxaban 15 mg BID × 3 weeks followed
by 20 mg daily. Standard therapy: enoxaparin 2.1%; standard therapy, 1.8%
1 mg/kg BID; bridging warfarin or
acenocoumarol therapy with target INR 2 to 3

VTE prevention

Intracranial bleeding

Ray and Keyrouz Critical Care 2014, 18:223
http://ccforum.com/content/18/3/223

Table 2 Intracranial hemorrhage rates reported in phase 3 clinical trials of dabigatran, rivaroxaban and apixaban related to stroke prevention and treatment
of acute venous thromboembolism

AICH (all): rivaroxaban, 0.49%/year
(P < 0.05); warfarin, 0.74%/year. ICH:
rivaroxaban, 0.33%/year; warfarin,
0.49%/year. SDH: rivaroxaban, 0.13%/year;
warfarin, 0.27%/year

AICH: rivaroxaban, 0.12%; standard
therapy, 0.50%

AF, atrial fibrillation; AICH, anticoagulant-related intracranial hemorrhage; ARISTOTLE, Apixaban for Reduction in Stroke and Other Thromboembolic Events; BID, twice daily; CAD, coronary artery disease; CHF, congestive
heart failure; DM, diabetes mellitus; DVT, deep venous thrombosis; EINSTEIN-PE, Oral Rivaroxaban Alone for the Treatment of Symptomatic Pulmonary Embolism; h/o, history of; INR, International Normalized Ratio; LVEF,
left ventricular ejection fraction; NYHA, New York Heart Association; PE, pulmonary embolism; RE-COVER, Efficacy and Safety of Dabigatran Compared to Warfarin for 6 Month Treatment of Acute Symptomatic Venous
Thromboembolism; RE-LY, Randomized Evaluation of Long Term Anticoagulant Therapy; ROCKET-AF, Rivaroxaban Once-daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of
Stroke and Embolism Trial in Atrial Fibrillation; SDH, subdural hematoma; TIA, transient ischemic attack; VKA, vitamin K antagonist; VTE, venous thromboembolism.
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reversal of coagulopathy in vivo as often demonstrated by
the expansion of AICH even after such correction [40].
Given the emergent nature of AICH and their unpredictability, randomized clinical trials or even large cohort studies in this population are unlikely and recommendations
regarding treatment strategies will continue to be based on
case series and anecdotal experience [43].

Principles and interpretation of monitoring
anticoagulant therapy
Evaluating and monitoring blood coagulation parameters is
imperative after AICH. This is particularly true when
obtaining history is difficult, thus precluding knowledge of
the culprit anticoagulant, information that is crucial to
guide therapy. Although coagulation tests are mere surrogate markers for hemostasis, the effect of different anticoagulants on the coagulation system is important knowledge
for the treating clinician to have. Some of these tests are
quantitative, and others provide only qualitative information. Moreover, it is important to understand that testing
techniques and their sensitivities vary widely especially with
newer anticoagulants [44].
Routine and commonly used ex vivo coagulation tests are
the prothrombin time (PT), INR, and activated partial
thromboplastin time (aPTT); the thrombin time, ecarin
clotting time, activated clotting time and endogenous
thrombin potential are also available, albeit less widely. The
plasma factors responsible for different coagulation assays
and their alteration with oral anticoagulants are presented
in Table 3 [45,46]. In patients with ongoing hemorrhage,
the PT is preferred over the aPTT for the estimation of
coagulation factor levels, because the results are quickly
available, it offers a good correlation with average factor

concentrations and response to plasma replacement, and
there is no interference with nonspecific lupus anticoagulant inhibitors, elevated factor VIII, and heparin contamination [47]. The modified thrombin time (also commercially
known as the HEMOCLOT thrombin time assay; Aniara,
West Chester, OH, USA) and ecarin clotting time are the
best tests for measuring the anticoagulant effect of
dabigatran [48]. A normal thrombin time would exclude
clinically significant dabigatran in systemic circulation. Although anti-factor IIa level testing is available at present,
not enough information on its characteristics is known –
such as linearity for and responsiveness in patients on dabigatran. To the contrary, the anti-factor Xa level has good
correlation with rivaroxaban/apixaban activity. The recommended test to measure the anticoagulant effect of rivaroxaban is the PT (using reagent Neoplastin Plus®; Diagnostica
Stago, Asnières-sur-Seine, France) and anti-factor Xa assay.
Dabigatran and rivaroxaban drug levels can be used as
surrogate markers to assess the need for anticoagulation
reversal, but they are also not widely available [48-50].
Both warfarin and heparin have good linear correlation
with the PT/INR and the aPTT respectively, but the utility
of the traditional coagulation profile testing is questioned
with the advent of newer anticoagulants (see Table 3).
Viscoelastic assays that measure whole blood coagulation
and provide a dynamic coagulation profile, such as thromboelastography and rotational thromboelastometry, are
being increasingly used to provide rapid assessment of
hemostasis [51]. These assays measure the increasing viscoelasticity of blood as it clots, which is proportional to
clotting factors and platelet count/function [52]. Their
advantages are a rapid turnaround time, and the detection
of fibrinolysis. Clinical situations where viscoelastic assays

Table 3 Interpretation of coagulation tests with US Food and Drug Administration approved oral anticoagulants
Coagulation
test

Factors
evaluated

Interpretation with
dabigatran

Interpretation with
apixaban

Interpretation with
rivaroxaban

Interpretation with
warfarin

PT

Factors II,
V, VII, X,
fibrinogen

Linear and dose dependent
prolongation; at therapeutic
range prolongs 1.2 times
the basal value

Prolonged but not well
studied or standardized

Linear and dose dependent
prolongation; at therapeutic
range prolongs 1.5 times the
basal value

Prolonged

aPTT

Factors II,
V, VIII, IX, X,
fibrinogen

Qualitative; prolongation dose
dependent but not linear; at
therapeutic range prolongs
2.5 times the basal value

Prolonged but not well
studied or standardized

May be prolonged
Linear and dose dependent
prolongation; at therapeutic
range prolongs 1.5 times the
basal value; not as sensitive as PT

TT

Fibrinogen

Data not available
Linear and dose dependent
prolongation; but prolongation
may be excessive and requires
dilution of the plasma samples

ECT

Factor II

Linear and dose dependent
prolongation; at therapeutic
range prolongs three times
the basal value

ETP

Factor II

Decreased – concentration
dependent

Not affected

Not affected

NA

NA

NA

Decreased – concentration
dependent

Decreased – concentration
dependent

NA

aPTT, activated partial thromboplastin time; ECT, ecarin clotting time; ETP, endogenous thrombin potential (thrombin generation assay); NA, not applicable; PT,
prothrombin time; TT, thrombin time.
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have been used to evaluate hemostasis include trauma
resuscitation [53], during cardiopulmonary bypass [54] and
AICH [55]. One study reported dose-dependent shortening
of the clot-lysis time in the presence of dabigatran [56].
These laboratory tests might hold promise in the near
future, although further studies and experience are needed.

Reversal of anticoagulation
Most authorities consider rapid and adequate reversal of
anticoagulation as the cornerstone of therapy in AICH,
despite the lack of evidence showing that correction of
coagulopathy reduces the incidence of hematoma growth
or improves outcome [40]. In certain situations, however –
such as the presence of a mechanical valve, INR < 3, small
hemorrhage, or no surgical intervention needed – some
authorities advocate holding warfarin without actively reversing coagulopathy [57]. Antidotes specific to each anticoagulant are presented in Table 1. Although warfarin
remains the most commonly used oral anticoagulant,
newer agents are gaining popularity. The exact mechanism
of the occurrence of WRICH remains speculative, but
potentially involves a local vasculopathy and/or systemic
factors (for example, higher prevalence of the apolipoprotein E ε2 allele in patients with WRICH) [11,58]. Preventative measures to mitigate WRICH could therefore be
relatively inefficient, and the onus is on rapid coagulopathy
reversal [59]. The same probably holds true for AICH related to newer anticoagulants. Hence, the first step in any
AICH is to discontinue the offending drug, administer an
antidote (if available) and monitor adequate reversal of anticoagulation. In the case of warfarin, theoretically adequate
hemostasis is restored at an INR of ~1.5 since adequate
quantities of the factors needed for ex vivo coagulation are
restored. However, an optimal INR value is unknown.
Unfortunately, parameters for adequate reversal with newer
anticoagulants are yet to be defined. Despite concern
among physicians for reversing anticoagulation in a prothrombotic state, available evidence with WRICH, albeit
meager, supports correcting the coagulopathy in such cases
[59-61].
Vitamin K

Vitamin K 5 to 10 mg intravenously by slow infusion over
30 minutes is administered to all patients with WRICH.
Anaphylactic reactions are uncommon, and are mitigated
by a slow infusion rate. The subcutaneous route for the administration of vitamin K is less effective because of erratic
absorption, and the enteral route provides slow absorption
although it has an equivalent bioavailability to the intravenous route [62]. The action of vitamin K is slow; it takes 6 to
24 hours to replenish adequate concentrations of factors II,
VII, IX and X and to restore hemostasis [63,64]. This warrants the administration of fresh frozen plasma (FFP), prothrombin complex concentrate (PCC) and/or recombinant
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activated factor VII (rFVIIa) to rapidly replenish deficient
factors. One should note that these agents have a short
half-life, and are practically used as bridging therapy until
vitamin K becomes effective.
Fresh frozen plasma

FFP contains all coagulation factors and is the most commonly used reversal agent in the USA due to its wide availability and physicians’ familiarity with it. The recommended
dose is anywhere between 10 and 40 ml/kg [12,64]; in clinical practice, however, FFP is commonly under-dosed for
fear of volume overload. Allergic reactions, possible transmission of infectious diseases, transfusion-related acute
lung injury [65] and, most importantly, a time lag to administration (due to thawing, cross-matching, prolonged infusion time) have sparked interest in a more optimal way to
replete factors. Lee and colleagues reviewed records of 45
patients with WRICH treated with FFP [66]. The median
time from door to INR normalization was 30 hours (14 to
49.5 hours), with four patients’ hematomas enlarging after
normalization. The disadvantages of using FFP can be
mitigated by procurement of male donors to minimize
transfusion-related acute lung injury or of universal (AB
group) donors, and by using liquid plasma – plasma that is
never frozen, thus bypassing the thawing process [67].
Prothrombin complex concentrate

Commonly available PCCs contain varying combinations
and concentrations of factor II, VII, IX and X, protein C,
protein S and protein Z. Some contain heparin and antithrombin to reduce thrombogenic potency. PCCs are
prepared from virally inactivated plasma, pooled from
several donors [43]. The concentrates come in two forms:
one containing the inactivated form of coagulation factors,
and another containing the activated form, such as FEIBA™
(Baxter, Deerfield, IL, USA).
Inactivated four-factor PCCs are available in Europe and
Australia. Until recently, only three-factor PCCs (factor II,
IX and X) have been used in the USA. Kcentra™ (CSL
Behring, King of Prussia, PA, USA) is the first inactivated
four-factor PCC approved by the US Food and Drug
Administration to correct warfarin-related coagulopathy.
The lack of comparative data on the efficacy of the
three-factor versus four-factor PCCs makes it difficult to
recommend one over the other [43], but the theoretical disadvantage of three-factor PCC led clinicians to supplement
it with either FFP or rFVIIa. In clinical practice, PCCs are
dosed based on factor IX content in a given preparation.
The half-lives of the component factors II, VII, IX, and X
are 60 hours, 4 to 6 hours, 17 to 24 hours, and 31 hours,
respectively [68]. The dose varies between 25 and 100
units/kg, depending on the degree of INR derangement,
and is infused, following reconstitution, at a rate of 100
units/minute [69,70]. The efficacy and safety of four-factor

Ray and Keyrouz Critical Care 2014, 18:223
http://ccforum.com/content/18/3/223

PCC as compared with FFP were demonstrated in a
recently reported randomized trial that showed faster repletion of coagulation factors and similar adverse effect profile
in either cohort [71].
FEIBA™ is an anti-inhibitor coagulant complex that is US
Food and Drug Administration approved for use in hemophiliacs. The complex has been used off-label in WRICH
[72]. The recommended dose of FEIBA™ is 500 to 1,000
units, and the infusion rate should not exceed 2 units/kg/
minute. The INR and fibrinogen should be checked
30 minutes after the end of infusion, and the dose may
need to be repeated. Cryoprecipitate may be needed if the
fibrinogen concentration is less than 100 mg/dl. Overcorrection of INR is possible and could lead to thrombotic
complications such as superficial thrombophlebitis, arterial
or venous thrombosis and disseminated intravascular coagulation. Such complications are mostly dose related and
their incidence in warfarin reversal is low [59]. Moreover,
these adversities could be partly due to the underlying
primary disease process [71,73,74]. An important factor
that limits the availability of PCCs is their prohibitive cost
[69], although a recent analysis suggested that they might
be more cost-effective than FFP for warfarin reversal after
life-threatening hemorrhages such as ICH [75].
Studies have demonstrated rapid and effective reversal of
the coagulopathy but PCC efficacy is still speculative in the
setting of WRICH [76,77]. In a study of 55 patients with
WRICH, 31 of whom were treated with PCC, there was
faster INR correction and reduction of hematoma growth
at 24 hours [76]. Conversely, in another study of 141 patients there was ICH expansion in 45.5% of patients, despite
correction of coagulopathy; in-hospital mortality was 42.3%
[40]. A retrospective study comparing FFP and PCC for the
reversal of warfarin’s effect in WRICH did not demonstrate
a significant difference in 30-day mortality [78]. An ongoing
randomized control study is set to shed more light on this
question [79]. In clinical practice, hemorrhages associated
with the use of newer anticoagulants (dabigatran, rivaroxaban, and apixaban) are also managed with infusion of PCCs
(25 to 50 units/kg) [80]. Both four-factor PCC and FEIBA™
(80 units/kg) have been demonstrated to increase thrombin
generation in healthy volunteers on dabigatran and rivaroxaban [45,81].
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PCC/FFP should be used concomitantly. Lower doses of 10
to 40 μg/kg are associated with a lower incidence of thrombotic complications [84,85]. Although INR is corrected
rapidly using rFVIIa, it may simply reflect the ex vivo effect
of factor VIIa on the PT assay and may not always correlate
with clinical hemostasis [86,87]. This is also reflected in the
ex vivo assays where rFVIIa has been shown to reverse INR
in patients on warfarin with minimal effect on aPTT and
bleeding time [88]. rFVIIa is effective in reversal of the anticoagulant effect of fondaparinux in healthy volunteers [89].
Its effectiveness, however, in fondaparinux-related ICH has
not yet been demonstrated [80]. Administration of rFVIIa
(120 μg/kg) in healthy volunteers on dabigatran and rivaroxaban did not correct thrombin generation tests [81]. The
long-term clinical impact of rFVIIa in patients with AICH
remains to be tested in prospective studies.
Protamine

For symptomatic ICH with supratherapeutic aPTT associated with UFH, the infusion should be stopped and residual
drug reversed using intravenous protamine sulfate at a ratio
of 1 mg protamine per 100 units of UFH that was infused
over the preceding 3 hours. Hemorrhagic conversion
remains a threat up to 48 hours following reversal. Caution
should be exercised by managing blood pressure [90],
and the aPTT should be followed to monitor heparin
neutralization. Side effects of protamine include hypotension, bradycardia, and anaphylactoid reactions. A
paradoxical anticoagulant effect can be minimized by infusing protamine slowly, over 3 minutes, and avoiding doses
greater than 50 mg at once. Protamine is less effective at
neutralizing low molecular weight heparin (LMWH)
because it only partially (60%) reverses its anti-factor Xa
effect [80,91]. A longer half-life of subcutaneously administered LMWH further contributes to their sustained effects.
Evidence-based guidelines on LMWH reversal is lacking.
Following the manufacturer’s recommendations, 1 mg protamine should be administered for every 1 mg enoxaparin
(Sanofi-Aventis, Bridgewater, NJ, USA), and 1 mg protamine for every 100 anti-Xa IU dalteparin (Eisai Co. Ltd,
Tokyo, Japan) or tinzaparin (LEO Pharmaceutical Products,
Ballerup, Denmark) that was administered in the preceding
8 hours. If bleeding persists, an additional half-dose of
protamine is recommended [80,91].

Recombinant activated factor VII

rFVIIa is a US Food and Drug Administration-approved
treatment for congenital factor VII deficiency and hemophiliacs with inhibitors to factor VIII. This treatment has
been used to correct coagulopathy associated with warfarin
[82]. rFVIIa has a dual mechanism of action that involves
initiating coagulation via the tissue factor and factor VIIa
pathway and direct platelet activation resulting in a thrombin burst [83]. Given its short half-life (3 to 4 hours), INR
reversal after rFVIIa dosing is transient, and vitamin K and

Antifibrinolytics

Tranexamic acid is an antifibrinolytic agent used for
prevention of re-rupture of cerebral aneurysm after subarachnoid hemorrhage. Long-term use of tranexamic acid
has been associated with hydrocephalus, thrombosis and
delayed cerebral ischemia in this patient population [92].
Concomitant blood pressure reduction and rapid infusion
of tranexamic acid has been shown to be associated with
less frequent hematoma expansion in spontaneous ICH not
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related to anticoagulant use [93]. Animal data on
hemostatic therapy with tranexamic acid in WRICH demonstrated lower efficacy as compared with PCC and rFVIIa
and worsening perihematomal edema [94]. Since no antidote is currently available for clinical use in dabigatranrelated major bleeding, some authorities recommend
administration of 1 g tranexamic acid [95]. In addition,
there is anecdotal experience of its use in a Jehovah’s Witness patient after post-tissue plasminogen activator-related
ICH to prevent hemorrhage expansion [96].
Special considerations with newer oral anticoagulants

To date, there are no specific antidotes available for clinical
use to reverse the anticoagulant effect of newer oral agents
such as dabigatran, apixaban, and rivaroxaban. Candidate
antidotes for dabigatran and factor Xa inhibitors have
demonstrated effectiveness in preclinical studies [97,98].
The proposed antidote for dabigatran is the antibody
aDabi-Fab that achieves an affinity for dabigatran 350 times
stronger than its affinity for thrombin. aDabi-Fab supposedly has no prothrombotic effect [98]. The antidote for
factor Xa inhibitors could have wider applicability in reversing both oral and parenteral agents, including LMWH and
fondaparinux. This antidote (PRT064445) reversed the
inhibition of factor Xa by direct factor Xa inhibitors and
corrected the prolongation of ex vivo clotting times in a
dose-dependent fashion. PRT064445 restored hemostasis
deranged by rivaroxaban in a rabbit model of liver
laceration [97]. In rats, the antidote dose-dependently and
completely corrected the increased blood loss caused by
enoxaparin and fondaparinux [97].
Until specific antidotes are available for clinical use, the
goal of treatment for AICH related to newer anticoagulants
is to restore coagulation by thrombin generation and to
overwhelm the effects of these agents with nonactivated
four-factor PCC, FEIBA™ or rFVIIa [99,100]. Other measures may include prevention of absorption by administering activated charcoal for recent ingestion and hemodialysis
or hemoperfusion [99]. The efficacy of prompt administration of activated charcoal has been demonstrated for dabigatran with in vitro models [99] and for rivaroxaban and
apixaban with in vivo animal models [101,102]. In patients
taking dabigatran and undergoing hemodialysis, there was
an 85% reduction in plasma level at 60 minutes with
charcoal hemoperfusion [103,104]. Rivaroxaban is unlikely
to be dialyzable due to its high protein binding, although it
may theoretically be eliminated via plasma exchange. In
emergency situations such as AICH, however, neither
hemodialysis nor plasma exchange is practically feasible.

Other supportive measures
The general management of patients with AICH is outlined
in recent guidelines published by the American Heart
Association [105]. Here, we elaborate on the acute
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management of hypertension and surgical interventions,
mostly relevant to intra-parenchymal bleed hemorrhages.
Anti-hypertensive therapy

In the acute phase of ICH, elevated blood pressure is
commonly encountered, with evidence linking acute hypertension to increased mortality, disability, and possibly risk of
hematoma growth [106,107]. One argument against aggressive treatment of acute hypertension in ICH, reducing
perfusion around the hematoma, was counteracted by
evidence from positron emission tomography studies
[108,109]. These studies and a handful of randomized controlled trials, most notably the INTERACT-2 (Intensive
Blood Pressure Reduction in Acute Cerebral Hemorrhage
Trial – 2) study, showed that aggressive blood pressure lowering in ICH to treat systolic blood pressure ≤140 mmHg is
safe [110]. Although a difference in primary outcome was
absent, there was improved morbidity among patients
undergoing aggressive systolic blood pressure control.
Results of an ongoing similar trial, the ATACH-II (Antihypertensive Treatment of Acute Cerebral Hemorrhage,
Phase III) trial, are awaited and could add to our knowledge
[111]. There remains a lack of consensus on how to manage
acutely elevated blood pressure in patients with AICH since
this population is excluded from acute ICH trials. However,
extrapolating results from spontaneous ICH trials seems
reasonable – although until such AICH trials are conducted,
clinicians should use clinical judgment and manage acute
hypertension on a case-by-case basis.
Surgery

The rationale to evacuate cerebral parenchymal hemorrhages is to prevent thrombin and hemoglobin degradationproduct-mediated secondary brain damage. In addition,
surgical removal of blood clots alleviates pressure gradients
inside the skull and restitutes normal anatomy, thus
reducing or abolishing pressure on and injury to vital midline diencephalic structures. There are no studies specifically
addressing the question of surgical evacuation of hematoma
in AICH, whether it is intra-parenchymal or elsewhere. In
clinical practice, and for obvious reasons, reversal of coagulopathy precedes potential hematoma evacuation.
Randomized trials for spontaneous ICH go back to the
early 1960s. The STICH trial (International Surgical Trial
in Intracerebral Hemorrhage) randomized over 1,000
patients to early surgery (within 24 hours of randomization)
or initial conservative treatment, but failed to show any
clinical benefit of surgical evacuation [112]. Subgroup
analysis indicating potential benefit of surgery in superficial
ICH (<1 cm from cerebral surface) was the basis for the
recently concluded STICH II trial, in which primary
intention-to-treat analysis showed a small but nonsignificant increase in the number of patients having a favorable
outcome at 6 months in the early surgery group. There was
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also a suggestion of a reduction in mortality, but this finding was also nonsignificant [113].
Surgical management after traumatic brain injury leading
to acute epidural or subdural hemorrhage is generally indicated if the Glasgow Coma Scale score is ≤8 and there is a
5 mm or more shift on head computed tomography
[114,115]. In a retrospective case series of 11 patients on
oral phenprocoumon (vitamin K antagonist) presenting
with acute subdural hemorrhage, the authors reported
mortality of 45.5% at 6 months and the remaining patients
were functionally independent during the same follow-up
period [116]. Given the acuity and associated high morbidity and mortality of AICH, it is difficult to systematically
study surgical therapy in this subgroup of patients.

Resumption of anticoagulation
Whether and when to resume anticoagulation are other
important questions that haunt clinicians managing AICH.
Again there is no straightforward and definitive answer to
this dilemma. Very few data are available to guide clinicians
on this important issue, and most of what we know is
generated by small case series. The decision of whether to
restart anticoagulation should take into consideration the
recent anticoagulant-related hemorrhage and the need for
anticoagulation. The evidence that supports use of anticoagulation in the disease process should be considered;
and the urgency with which anticoagulation needs to be
restarted and the risk of trauma/falls leading to rebleeding
should also be a factor. The presence of microbleeds on
brain magnetic resonance imaging might portend a higher
risk of developing recurrent AICH once anticoagulation is
restarted [117]. Finally, the availability of alternative approaches, in lieu of anticoagulation, to prevent progression
of or complications from a thromboembolic disease process
should be sought (for example, newer anticoagulants,
temporary vena cava filter devices).
Claassen and colleagues reviewed medical records of 52
consecutive patients with WRICH [118]. Warfarin was
restarted after a median of 10 days (range 7 to 28 days) in
23 patients; one-half of these had mechanical heart valves.
During follow-up there were five cases of recurrent major
bleeding in the group on warfarin, and five thromboembolic events in those not restarted on warfarin. In another retrospective study, Majeed and colleagues identified
234 patients with WRICH, 177 of whom had long-term
follow-up [119]. Of these 177 patients, 59 resumed warfarin
after a median of 5.6 weeks. Recurrent ICH occurred in
eight patients who restarted warfarin and in 10 patients
who did not. The combined risk of recurrent WRICH or ischemic stroke reached its nadir when warfarin was resumed 10 to 30 weeks after the incident WRICH.
In patients with a mechanical valve, the annual risk of
systemic embolism is 4% per year, and the risk of valve
thrombosis is 1.8% [59,64,120]. Given the risk of hematoma
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expansion and subsequent high morbidity associated with
WRICH, it is advisable to withhold anticoagulation in the
acute phase [59]. In the 2010 version of the American
Heart Association guidelines, a specific mention of time to
restart anticoagulation after WRICH was omitted [105].
The European stroke initiative suggests balancing the risk
of recurrent ICH and thromboembolism in individuals with
a strong indication for anticoagulation, and reinitiating the
latter 10 to 14 days after the incident WRICH [64]. Practically, resumption of anticoagulation is debated among stroke
experts and most agree to restart anticoagulation in 7 to
14 days provided benefits outweigh the risk and if the
hemorrhage was deep in location [121].

Conclusion
Many questions pertaining to the management of AICH
remain unanswered. Conducting a systematic randomized trial in this subpopulation of patients is difficult.
The available literature (although mostly retrospective
and case series) recommends rapid correction of
coagulopathy, early surgical intervention if appropriate
and holding resumption of anticoagulation during the
acute phase. Newer oral anticoagulants are marketed to
be safe with lower incidence of AICH and can be
potentially considered when resumption of anticoagulation is warranted. However, the lack of optimal reversal
agent in case of complications may deter clinicians from
using them. The development of safe and novel reversal
agents for newer generation anticoagulants should thus
take precedence, given their booming use and the
current naivety and inexperience of the healthcare
provider in managing their hemorrhagic complications.
Better studies are needed to guide clinicians in appropriate management and to help prognostication. Given the
overall poor functional outcome of patients with ICH in
general, and perhaps AICH in particular, a need exists to
explore preventative avenues. Hence, emphasis should
be also placed on patient education, lifestyle and risk
modification and discussion of the risk–benefit ratio
before anticoagulants are prescribed.
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